This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

aaiPharma Switches CEOs Again

For the second time in less than a year, aaiPharma (AAII) has changed its top management.

The Wilmington, N.C.-based drug company said Tuesday that Frederick D. Sancilio, 54, the company's founder, would immediately step down as chairman, chief executive, president and chief science officer. Sancilio, however, will remain as a nonexecutive member of the board of directors of the ailing company .

The new president and CEO is Ludo Reynders, 50, who most recently held executive posts at Quintiles Transnational, a medical research services unit of Pharma Services in Durham, N.C.

In addition, aaiPharma chose a new nonexecutive chairman of the board, James G. Martin. He has been a board member since 1999 and is an executive with Carolinas HealthCare System, a regional health care organization. Martin, 68, was governor of North Carolina from 1984 to 1992.

The new management team joins a company whose stock has dropped by about 95% from its 52-week high of $31.85 on Jan. 21. In premarket trading Tuesday, the stock gained 21 cents, or 15.6%, to $1.56.

Sancilio returned to daily management in February, replacing Dr. Philip Tabbiner as CEO. Tabbiner joined aaiPharma in 2000 and became CEO in July 2002. So far this year, aaiPharma has replaced its chief operating officer, chief financial officer and several other top executives.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs